Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large kenyan cohort

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Kigen, Gabriel ^a,b   Kimaiyo, Sylvester ^a   Nyandiko, Winstone ^a   Faragher, Brian ^c   Sang, Edwin ^a   Jakait, Beatrice ^a   Owen, Andrew ^b   Back, David ^b   Gibbons, Sara ^b   Seden, Kay ^d   Khoo, Saye H ^b,d  

^a MOI UNIVERSITY   (Kenya)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^d ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ARTEMETHER PLUS BENFLUMETOL; DAPSONE; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; FLUCONAZOLE; FLUOXETINE; KETOCONAZOLE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LANSOPRAZOLE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; OMEPRAZOLE; PREDNISONE; RIFAMPICIN; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PREVALENCE; SCREENING; WORLD HEALTH ORGANIZATION; DRUG COMBINATION; DRUG INTERACTION; DRUG TOXICITY; EVALUATION; MIDDLE AGED; PHYSIOLOGY; POLYPHARMACY; SAMPLE SIZE;

ADULT; AGED; ANTI-HIV AGENTS; COHORT STUDIES; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG TOXICITY; FEMALE; HIV INFECTIONS; HUMANS; KENYA; MALE; MIDDLE AGED; POLYPHARMACY; PREVALENCE; SAMPLE SIZE; YOUNG ADULT;

EID: 79952029064     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016800     Document Type: Article

References (31)

1. Berrey MM, Schacker T, Collier AC, Shea T, Brodie SJ, et al. (2001) Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis 183 (10): 1466-75.
2. Smith PF, DiCenzo R, Morse GD, (2001) Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 40 (12): 893-905.
3. de Maat MM, Ekhart GC, Huitema AD, Koks CH, Mulder JW, et al. (2003) Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet 42 (3): 223-82.
4. Huang L, Wring SA, Woolley JL, Brouwer KR, Serabjit-Singh C, et al. (2001) Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos 29 (5): 754-60.
5. Young B, (2005) Review: mixing new cocktails: drug interactions in antiretroviral regimens. AIDS Patient Care STDS 19 (5): 286-97.
6. Robertson SM, Penzak SR, Pau A, (2007) Drug interactions in the management of HIV infection: an update. Expert Opinion Pharmacother 8 (17): 2947-63.
7. de Maat MM, de Boer A, Koks CH, Mulder JW, Meenhorst PL, et al. (2004) Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care. J Clin Pharm Ther 29 (2): 121-30.
8. Shah S, McGowan J, Opulski B, A Lieblein A, Saperstein A, (2007) Identification of Drug Interactions Involving ART in New York City HIV Specialty Clinics, In: Program and abstracts of the 14th conference on Retroviruses and Opportunistic Infections; February 25-28, Abstr 573.
9. Miller CD, El-Kholi R, Faragon JJ, Lodise TP, (2007) Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy. Pharmacotherapy 27 (10): 1379-86.
10. Marzolini C, Elzi L, Gibbons S, Weber R, Fux C, et al. (2010) Prevalence of co-medications and impact of potential drug-drug interactions in the Swiss HIV Cohort Study. Antiviral Ther 15: 413-23.
11. Evans-Jones JG, Cottle LE, Back DJ, Gibbons S, Beeching NJ, et al. (2010) Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 50 (10): 1419-21.
12. medicine.iupui.edu/kenya/index.html (accessed between January to August 2008).
13. NASCOP. (2005) Guidelines to Antiretroviral Drug Therapy in Kenya. 3rd ed. Nairobi, Kenya Republic of Kenya, Ministry of Health.
14. www.hiv-druginteractions.org (accessed between January to August 2009).
15. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, et al. (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ Apr 26;336 (7650): 924-6.
16. Tatro. (2008) Drug interaction Facts. Facts and Comparisons, St. Louis, Missouri.
17. Viramune Summary of Product Characteristics (January 2007). Boehringer Ingelheim International GmbH.
18. Ramachandran G, Hemanthkumar AK, Rajasekaran S, Padmapriyadarsini C, Narendran G, et al. (2006) Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration. J Acquir Immune Defic Syndr 42 (1): 36-41.
19. Sustiva Summary of Product Characteristics (January 2007), Bristol-Myers Squibb Pharmaceuticals Ltd.
20. Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, et al. (2008) Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 300: 530-539.
21. la Porte CJ, Colbers EP, Bertz R, Voncken DS, Wikstrom K, et al. (2004) Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother48 (5): 1553-60.
22. McIlleron H, Ren Y, Nuttall J, Fairlie L, Rabie H, et al. Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis. Antivir Ther 2011 (in press).
23. Davies G, Cerri S, Richeldi L, Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev 2007 Oct 17;(4):CD005159.
24. Boulanger C, Hollender E, Farrell K, Stambaugh JJ, Maasen D, et al. (2009) Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis 49 (9): 1305-11.
25. Lamson M, Robinson P, Lamson M, Gigliotti M, Myers MW, (1998) The pharmacokinetic interactions of nevirapine and ketoconazole. International Conference on AIDS. Int Conf AIDS 12: 55 (abstract no12218).
26. Wakeham K, Parkes-Ratanshi R, Watson V, Ggayi A, Khoo S, et al. (2010) Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans. J Antimicrobial Chemother 65 (2): 316-9.
27. German P, Parikh S, Lawrence J, Dorsey G, Rosentha, P J, et al. (2009) Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immun Defic Syndr 51 (4): 424-9.
28. Davies MA, Moultrie H, Eley B, Rabie H, Van Cutsem G, et al. (2010) Virologic failure and second-line antiretroviral therapy in children in South Africa- The IeDEA Southern Africa Collaboration. J Acquir Immune Defic Syndr 2011. [Epub ahead of print].
29. Marseille E, Kahn JG, Pitter C, Bunnell R, Epalatai W, et al. (2009) The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda. Appl Health Econ Health Policy 7 (4): 229-43.
30. DART Trial Team (2010) Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 375 (9709): 123-131.
31. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach (2010 version). Available fromhttp://www.who.int/hiv/pub/arv/adult2010/en/index.html.